Frontiers in Neurology
K. Hänninen, M. Viitala, T. Paavilainen, J. Karhu, J. Rinne, J. Koikkalainen, J. Lötjönen, M. Soilu-Hänninen
Using cNeuro® cMRI, global and regional brain volumes were measured 6 months after treatment initiation for newly diagnosed relapsing multiple sclerosis (MS) patients and in patients with secondary progressive MS. Other measures included z scores (compared with healthy controls), the Expanded Disability Status Scale (EDSS), and relapse. The aim was to determine if thalamic atrophy can predict 5-year disability progression in patients with MS. Baseline thalamic volume was associated with greater use of disease-modifying therapies and predicted disability at 5 years, indicating that brain volume measurement could be important for prediction of MS progression and could aid treatment decisions.
